tocilizumab
roche
['toci', 'mmsm']
crs 56% at 2d response to toci, and icans low. infections 67%. again noted as a promising therapy in heavily pretreated patients refractory to many key therapies. #ash22 #imfash22 #mmsm 
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.